WHONET Webinar Series: Macro and Quick Analysis Reports
Explore the WHONET Webinar Series focusing on Macros and Quick Analysis Reports by John Stelling, MD, MPH. Learn about data analysis, creating, using, and editing macros, standard and user-defined reports, and WHONET Automation Tool. Discover the future webinar topics and how WHONET macros can strea
6 views • 22 slides
Overview of 2023 Mathematics Framework Webinar by California Department of Education
California Department of Education held a webinar to introduce the 2023 Mathematics Framework for Public Schools. Key points covered include core ideas, guidance for instructional planning, chapters overview, and the purpose of the webinar. The framework emphasizes effective and equitable math instr
0 views • 45 slides
Guidelines for Treating Chronic Hepatitis C Virus Infection
Clinical guidelines provide evidence-based recommendations for treating and curing chronic HCV infection in adults to improve treatment rates, reduce morbidity and mortality, and support the New York State Hepatitis C Elimination Plan. Recommendations include considerations in HCV treatment initiati
2 views • 28 slides
HCV Utilization Webinar
Today's webinar covers topics such as 2023 reconciliation, 2024 funding projections, PIC data cleanup, special purpose voucher updates, and more. Presenters from the US Department of Housing & Urban Development share important information and reminders regarding VMS data submission deadlines, eVMS u
0 views • 17 slides
LiveRx Study - Eradicating Hepatitis C in Alberta
LiveRx Study aims to evaluate the impact of a collaborative program involving community pharmacies and organizations in treating HCV in Alberta. By leveraging pharmacist-led interventions, the initiative focuses on increasing HCV screening, diagnosis, and linkage to care, ultimately aiming to eradic
2 views • 13 slides
NNDSS Updates and Changes for 2024 Webinar Highlights
The Centers for Disease Control and Prevention (CDC) shared important updates and announcements during the NNDSS eSHARE January Webinar in 2024. Topics included changes based on CSTE position statements, new NNDSS diseases, conditions, event codes, and more. The webinar covered the Total Message Map
5 views • 37 slides
Community Mental Health Survey Trust Webinar Overview
Conducted annually since 2004, the Community Mental Health Survey Trust Webinar provides insights into mental health services, participation, results usage, and eligibility criteria. The survey's impact on NHS performance, CQC assessments, and service improvement planning is highlighted, emphasizing
0 views • 22 slides
Understanding the Housing Choice Voucher (HCV) Homeownership Program
The Housing Choice Voucher (HCV) Homeownership Program helps low-income, first-time homebuyers by providing monthly housing assistance payments. This presentation covers key aspects such as program overview, steps to develop the program, operations, counseling, eligible housing, inspections, financi
0 views • 71 slides
HHS-RADV Webinar Series: 2019 Benefit Year Updates
Join the HHS-RADV webinar series for updates on protocols and guidelines for the 2019 benefit year. Learn about session agenda, stakeholder guidelines, Q&A submissions, and technical tips for optimal webinar experience.
0 views • 57 slides
Best Practices in Waitlist Management Webinar
This webinar focuses on best practices in waitlist management for the HCV program. It covers topics such as program updates, waitlist rules, regulations, and best practices from various housing authorities. The content discusses the purpose of the waiting list, opening the waiting list, conducting o
0 views • 33 slides
UK Climate Resilience Programme Webinar Series 2022
The UK Climate Resilience Programme is hosting a webinar series featuring prominent speakers discussing key topics related to climate change adaptation, impacts, and decision-making options. Presentations and Q&A sessions will cover insights from the IPCC WGII report, projected risks associated with
1 views • 10 slides
Updates on Intermacs/Pedimacs Quality Reporting Webinar and Covid-19 Guidelines
April 20, 2023, marks the date for the Society of Thoracic Surgeons' upcoming webinar focusing on Intermacs/Pedimacs data reporting, updates, and processes. The webinar covers important topics such as telehealth visits, quality of life surveys, data utilization, and contact information for database
1 views • 14 slides
UN-REDD Webinar Series: Guidelines for Presenters & Event Promotion
Delve into the comprehensive guidelines for both presenters and event promotion for the UN-REDD webinar series. Learn how to define the purpose of your webinar, plan and promote the event effectively, and engage the audience skillfully. Discover essential tips on developing presentations, preparing
1 views • 12 slides
Initial Teacher Certification Webinar Overview
This content provides detailed information about an Initial Teacher Certification Webinar hosted by the Office of Certification and Professional Preparation on April 25, 2018. It covers various topics including certification applications, renewal procedures, adding endorsements, TeachWV.com resource
0 views • 34 slides
Fall 2014 Pre-Administration Webinar for Georgia High School Graduation Test
The Fall 2014 Pre-Administration Webinar provides important information regarding the Georgia High School Graduation Test (GHSGT) for the 2014-2015 academic year. It covers test administration dates, new procedures, enrollment counts, reminders, and deadlines. The webinar emphasizes the use of prope
1 views • 55 slides
Advances in Hepatitis C Treatment for HIV-Infected Patients: A Comprehensive Overview
Explore the latest advancements in the treatment of Hepatitis C virus (HCV) in HIV-infected individuals through a detailed presentation by Dr. Kara W. Chew. Learn about the initial evaluation for HCV, treatment options for different genotypes, management of advanced fibrosis, recommended approaches
0 views • 9 slides
Supporting Harm Reduction and Health Care in Prisons
PASAN (Prisoners with HIV/AIDS Support Action Network) in Ontario exclusively works with prisoners and ex-prisoners to provide support, education, and advocacy related to HIV/HCV and harm reduction. They aim to ensure healthcare access and continuity of care for prisoners living with HIV/HCV, combat
0 views • 20 slides
ENERGY STAR Laboratory Grade R/F Webinar Summary
The ENERGY STAR Laboratory Grade R/F Webinar held on October 23, 2013, featured presentations by Bryan Berringer from the U.S. Department of Energy and Christopher Kent from the U.S. Environmental Protection Agency. The webinar covered topics such as DOE validation testing, test data analysis, draft
0 views • 41 slides
Decline of Hepatitis C in England: 2022 Report Highlights
The 2022 report on Hepatitis C in England shows a continued decline in the prevalence of chronic HCV infection, with around 81,000 individuals estimated to be affected in 2020. The report also highlights the distribution of infections among individuals with different drug injecting histories. Data f
0 views • 41 slides
HCV Webinar Highlights & Program Updates - April 18, 2024
Today's webinar covers updates on 2024 funding, income protections, and program resources. Details include new funding timelines, highlights of the 2024 appropriations, combating source of income discrimination, and more. Stay informed and engaged with the latest developments in the HCV program.
0 views • 17 slides
Hepatitis C Screening Recommendations for Adults (2017)
The Canadian Task Force on Preventive Health Care (CTFPHC) released recommendations on Hepatitis C screening for adults in 2017. The guidelines provide an overview of screening methods, key findings, implementation considerations, and conclusions. Those at higher risk for HCV in Canada include indiv
0 views • 38 slides
VA Innovation and Research Review System (VAIRRS) Monthly Webinar Highlights
This monthly webinar for VA Innovation and Research Review System (VAIRRS) provides key updates and information for attendees. Topics covered include housekeeping instructions, upcoming events, important announcements such as COVID-19 research dashboard and VAEDA webinar, and a focus on IRBNet basic
0 views • 49 slides
Risk of HCV Reinfection Among HIV/HCV Co-Infected Individuals in Europe
In the absence of an HCV vaccine, individuals cured of HCV are still at risk of reinfection, particularly among HIV-co-infected populations. This study aims to examine the risk of reinfection within 2 years of achieving sustained virological response in Europe. Regional differences, treatment regime
0 views • 19 slides
Comparison of Simeprevir vs. Telaprevir in HCV Genotype 1 Non-Responders
The ATTAIN study compared simeprevir and telaprevir in previous non-responders with genotype 1 HCV. The study included 379 patients with simeprevir and 384 with telaprevir, focusing on SVR12 as the primary endpoint. Baseline characteristics, treatment regimens, patient disposition, and virologic out
0 views • 6 slides
Overview of Hepatitis C Epidemiology in Ghana by Dr. Fred Stephen Sarfo
Dr. Fred Stephen Sarfo's research on Hepatitis C in Ghana reveals a notable sero-prevalence of the virus across various populations such as blood donors, prisons inmates, and more. The studies show varying HCV antibody frequencies, highlighting the need for continued surveillance and targeted interv
0 views • 25 slides
California School Finance Authority SB740 Webinar Overview
The California School Finance Authority is hosting a webinar on May 6, 2020, to provide information on the SB740 program, which offers funding to assist charter schools with facility costs. The program aims to support schools demonstrating a need for financial assistance and serving students eligibl
0 views • 23 slides
C-EDGE.TN Study: Grazoprevir/Elbasvir in Genotype 1, 4, or 6 - Treatment for HCV Infection
The C-EDGE.TN Study evaluated the efficacy of grazoprevir/elbasvir treatment in patients with HCV infection, specifically genotype 1, 4, or 6. The study included 316 patients and aimed to achieve SVR12 rates superior to historical standards. The treatment was well-tolerated, with high SVR12 rates ac
0 views • 9 slides
Efficacy of Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir with Ribavirin in Liver Transplant Recipients with Recurrent HCV GT1
The CORAL-I trial evaluated the safety and efficacy of the 3D regimen (ombitasvir-paritaprevir-ritonavir + dasabuvir) combined with ribavirin for 24 weeks in liver transplant recipients with recurrent HCV genotype 1. The study included treatment-naive individuals after transplantation, with specific
0 views • 8 slides
Healthcare Utilization in Quebec Immigrants and Non-Immigrants with Chronic Hepatitis C Infection
This study, supervised by Dr. Christina Greenaway, aims to estimate and compare healthcare utilization in Quebec immigrants and non-immigrants diagnosed with chronic Hepatitis C infection. The research seeks to identify predictors of all-cause and liver-related healthcare utilization. With rising he
0 views • 25 slides
Daclatasvir + Sofosbuvir + Ribavirin in HCV GT-3 Advanced Liver Disease: ALLY-3+ Trial
The ALLY-3+ Trial investigates the efficacy of daclatasvir, sofosbuvir, and ribavirin in patients with chronic HCV GT-3 and advanced liver disease. This Phase 3 study compared 12 versus 16 weeks of treatment in treatment-naive or experienced individuals. Results showed promising SVR12 rates and favo
0 views • 9 slides
Effectiveness of Daclatasvir and Sofosbuvir in HCV Genotype 3: Insights from ALLY-3 Study
Study on the efficacy of Daclatasvir and Sofosbuvir in treating Hepatitis C Virus (HCV) Genotype 3, involving treatment-naive and treatment-experienced patients. The Phase 3 trial showcased promising results in achieving SVR12, with detailed patient characteristics, drug dosing, and baseline charact
0 views • 10 slides
Therapeutic Trials in HIV/HCV Coinfection: ION-4, Ally-2, and Viroteam 2015
In the study of therapeutic trials in HIV/HCV coinfection between 2014-2015, notable trials included ION-4 with LDV/SOF treatment for 12 weeks in HCV/HIV co-infection patients, showing high SVR rates in both treatment-naive and experienced patients. Another trial, Ally-2, involved Daclatasvir and So
0 views • 15 slides
Enhancing Leasing Success with Administrative Fee Utilization
This webinar focuses on utilizing administrative fees to improve leasing success in the HCV program. It covers topics such as funding determination, best practices in administrative fee usage, and permissible uses of administrative fee funding. Participants can learn about how administrative fees ar
0 views • 29 slides
Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection
This presentation by Dr. Ricardo A. Franco focuses on the challenges faced in managing and treating patients with HIV/Hepatitis C virus coinfection. It discusses the burden of HCV mono-infection and HIV/HCV co-infection, the impact of HIV co-infection on survival in HCV-related cirrhosis, and the ro
0 views • 26 slides
C-EDGE.CO-STAR: Grazoprevir/Elbasvir for HCV Infected Drug Users on Opioid Replacement Therapy
A study on the effectiveness of grazoprevir/elbasvir in treating HCV-infected individuals on opioid replacement therapy. The study aimed to achieve SVR12 with immediate treatment and compared results to deferred treatment. The primary endpoint SVR12 was achieved in a high percentage of patients on i
0 views • 15 slides
Study on Elbasvir/Grazoprevir with or without Ribavirin in HCV Patients
The C-EDGE.experienced Study investigated the use of Elbasvir/Grazoprevir with or without Ribavirin in patients who failed prior therapy with PEG-IFN and Ribavirin. The study had 105 participants and aimed to achieve an SVR12 rate of over 95%. Results showed high SVR12 rates in both treatment arms,
0 views • 14 slides
Comparison of SOF+RBV vs PEG-IFN-2a+RBV for HCV Genotype 2 and 3 Treatment
FISSION Study compared the efficacy of SOF+RBV and PEG-IFN-2a+RBV for HCV genotypes 2 and 3 in treatment-naive patients with chronic HCV infection. The study included 256 participants in the SOF+RBV group and 243 in the PEG-IFN-2a+RBV group. The primary objective was to determine the non-inferiority
0 views • 6 slides
Simeprevir Combination Therapy in Treatment-Naïve HCV Genotype 1 Patients: QUEST-1 Trial Results
The QUEST-1 trial evaluated the efficacy and safety of simeprevir in combination with peginterferon and ribavirin versus peginterferon and ribavirin alone in treatment-naïve patients with chronic HCV genotype 1 infection. The study showed a significantly higher proportion of patients achieving sust
0 views • 14 slides
Simeprevir Treatment in HCV Genotype 1: ASPIRE Trial Results
The ASPIRE trial evaluated simeprevir treatment in patients with treatment-experienced chronic HCV genotype 1 infection. The study design included different dosing regimens of simeprevir with peginterferon and ribavirin, compared to placebo. Results showed varying sustained virologic response rates
0 views • 9 slides
Study on GZR, EBR, and MK-3682 for Chronic HCV Infection
The C-CREST study, Part A, focuses on the Phase II design of GZR, EBR, and MK-3682 treatment for genotypes 1, 2, and 3 in chronic HCV infection. The study includes baseline characteristics, SVR12 endpoint, impact of NS5A RAVs, and treatment outcomes. Results show promising SVR rates with different r
0 views • 8 slides